WallStSmart

General Motors Company (GM)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

General Motors Company generates 1411% more annual revenue ($184.62B vs $12.22B). VRTX leads profitability with a 35.5% profit margin vs 1.4%. GM appears more attractively valued with a PEG of 0.34. VRTX earns a higher WallStSmart Score of 66/100 (B-).

GM

Buy

52

out of 100

Grade: C-

Growth: 3.3Profit: 4.5Value: 8.0Quality: 4.3
Piotroski: 3/9Altman Z: 1.19

VRTX

Strong Buy

66

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 6.7Quality: 8.0
Piotroski: 3/9Altman Z: 3.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

GMUndervalued (+24.0%)

Margin of Safety

+24.0%

Fair Value

$105.05

Current Price

$78.80

$26.25 discount

UndervaluedFair: $105.05Overvalued
VRTXUndervalued (+57.2%)

Margin of Safety

+57.2%

Fair Value

$992.87

Current Price

$429.82

$563.05 discount

UndervaluedFair: $992.87Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GM4 strengths · Avg: 9.3/10
PEG RatioValuation
0.3410/10

Growing faster than its price suggests

Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Market CapQuality
$70.70B9/10

Large-cap with strong market position

Free Cash FlowQuality
$1.44B8/10

Generating 1.4B in free cash flow

VRTX6 strengths · Avg: 9.7/10
Profit MarginProfitability
35.5%10/10

Keeps 36 of every $100 in revenue as profit

Operating MarginProfitability
38.1%10/10

Strong operational efficiency at 38.1%

EPS GrowthGrowth
61.4%10/10

Earnings expanding 61.4% YoY

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$107.87B9/10

Large-cap with strong market position

Return on EquityProfitability
24.2%9/10

Every $100 of equity generates 24 in profit

Areas to Watch

GM4 concerns · Avg: 3.3/10
P/E RatioValuation
28.6x4/10

Moderate valuation

Return on EquityProfitability
4.0%3/10

ROE of 4.0% — below average capital efficiency

Profit MarginProfitability
1.4%3/10

1.4% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
2.104/10

Expensive relative to growth rate

P/E RatioValuation
25.3x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : GM

The strongest argument for GM centers on PEG Ratio, Price/Book, Market Cap. PEG of 0.34 suggests the stock is reasonably priced for its growth.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.

Bear Case : GM

The primary concerns for GM are P/E Ratio, Return on Equity, Profit Margin. Thin 1.4% margins leave little buffer for downturns.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

GM profiles as a value stock while VRTX is a mature play — different risk/reward profiles.

GM carries more volatility with a beta of 1.29 — expect wider price swings.

VRTX is growing revenue faster at 7.8% — sustainability is the question.

GM generates stronger free cash flow (1.4B), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (66/100 vs 52/100), backed by strong 35.5% margins. GM offers better value entry with a 24.0% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

General Motors Company

CONSUMER CYCLICAL · AUTO MANUFACTURERS · USA

General Motors Company (GM) is an American multinational corporation headquartered in Detroit, Michigan that designs, manufactures, markets, and distributes vehicles and vehicle parts, and sells financial services, with global headquarters in Detroit's Renaissance Center.

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?